XML 38 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration Agreements and Revenues (Tables)
6 Months Ended
Jun. 30, 2020
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue Product revenue, net was as follows (in thousands):

 

 

 

Three Months Ended June 30, 2020

 

 

Six Months Ended June 30, 2020

 

Gross revenue

 

$

19,833

 

 

$

25,205

 

Non-key account hospital listing award

 

 

(2,566

)

 

 

(2,566

)

Contractual sales rebate

 

 

(1,372

)

 

 

(1,748

)

Other discounts and rebates

 

 

(202

)

 

 

(243

)

Product revenue, net

 

$

15,693

 

 

$

20,648

 

 

Roll-forward of Contract Liabilities The following table includes a roll-forward of the contract liabilities (in thousands):

 

 

Balance at December 31, 2019

 

 

Additions

 

 

Deduction

 

 

Currency Translation and Other

 

 

Gross Contract Liabilities Balance

 

 

Balance Presented Net Against Accounts Receivable

 

 

Balance at June 30, 2020

 

Contract liabilities

 

$

(1,102

)

 

$

(4,907

)

 

$

16

 

 

$

9

 

 

$

(5,984

)

 

$

5,595

 

 

$

(389

)

Summary of Contra-Accounts Receivable Items Related to Product Revenue

The above-mentioned contra-accounts receivable items related to product revenue consisted of the following (in thousands):

 

 

June 30, 2020

 

 

December 31, 2019

 

Price adjustment

 

$

935

 

 

$

936

 

Contractual sales rebate

 

 

1,878

 

 

 

148

 

Non-key account hospital listing award

 

 

2,567

 

 

 

 

Other discounts and rebates

 

 

260

 

 

 

18

 

Provision for credit loss

 

 

84

 

 

 

 

Total reductions to gross accounts receivable

 

$

5,724

 

 

$

1,102

 

 

Japan [Member]  
Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Japan Agreement were as follows (in thousands): 

 

 

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

Agreement

 

Performance Obligation

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Japan

 

License revenue

 

$

 

 

$

 

 

$

 

 

$

 

 

 

Development revenue

 

$

164

 

 

$

369

 

 

$

327

 

 

$

615

 

 

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

 

Japan Agreement

 

Cumulative

Revenue

Through

June 30, 2020

 

 

Deferred

Revenue at

June 30, 2020

 

 

Total

Consideration

Through

June 30, 2020

 

License

 

$

86,024

 

 

$

 

 

$

86,024

 

Development revenue

 

 

15,458

 

 

 

183

 

 

 

15,641

 

Total license and development revenue

 

$

101,482

 

 

$

183

 

 

$

101,665

 

Europe [Member]  
Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

 

 

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

Agreement

 

Performance Obligation

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Europe

 

License revenue

 

$

 

 

$

117,470

 

 

$

 

 

$

117,470

 

 

 

Development revenue

 

$

4,602

 

 

$

16,854

 

 

$

9,176

 

 

$

21,467

 

 

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):

 

Europe Agreement

 

Cumulative

Revenue

Through

June 30, 2020

 

 

Deferred

Revenue at

June 30, 2020

 

 

Total

Consideration

Through

June 30, 2020

 

License

 

$

487,951

 

 

$

 

 

$

487,951

 

Development revenue

 

 

240,184

 

 

 

2,338

 

 

 

242,522

 

Total license and development revenue

 

$

728,135

 

 

$

2,338

 

 

$

730,473

 

 

U.S./RoW and China [Member]  
Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands):

 

 

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

Agreement

 

Performance Obligation

 

2020

 

 

2019

 

 

2020

 

 

2019

 

U.S. / RoW

and China

 

License revenue

 

$

 

 

$

33,111

 

 

$

 

 

$

33,111

 

 

 

Development revenue

 

 

13,750

 

 

 

23,762

 

 

 

28,305

 

 

 

42,766

 

 

 

China performance obligation

 

$

441

 

 

$

 

 

$

594

 

 

$

 

 

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands):

 

U.S. / RoW and China Agreements

 

Cumulative

Revenue

Through

June 30, 2020

 

 

Deferred

Revenue at

June 30, 2020

 

 

Total

Consideration

Through

June 30, 2020

 

License

 

$

341,844

 

 

$

 

 

$

341,844

 

Co-development, information sharing &

  committee services

 

 

521,572

 

 

 

4,547

 

 

 

526,119

 

China performance obligation

 

 

684

 

 

 

140,973

 

 

 

141,657

 

Total license and development revenue

 

$

864,100

 

 

$

145,520

 

 

$

1,009,620